Table 1.

Summary table of densitometry quantifications for cNICD and mNICD in inhibitor assays

DOI: http://dx.doi.org/10.7554/eLife.05842.011

Treatment	N	Mean adjusted relative fold change of cNICD protein	± standard error of the mean	Statistical test	p-value
XAV939	9	3.078	±0.776	One-sample T-test	0.0280*
XAV939 (no CHX)	5	2.491	±0.480	One-sample T-test	0.0361*
Roscovitine	10	1.94	±0.255	One-sample Signed Rank test	0.002*
Roscovitine (no CHX)	7	1.594	±0.146	One-sample T-test	0.00653*
DRB	8	2.557	±0.702	One-sample Signed Rank test	0.008*
DRB (no CHX)	6	1.369	±0.081	One-sample T-test	0.00601*
Cyclopamine	2	1.263	±0.106	One-sample T-test	0.244
PHA767491	2	3.479	±0.451	One-sample T-test	0.115
MLN4924	3	8.831	±2.734	One-sample T-test	0.103

Treatment	N	Mean adjusted relative fold change of mNICD protein	± Standard error of the mean	Statistical test	p-value
XAV939	8	2.221	±0.396	One-sample signed rank test	0.008*

^*demarcates a statistically significant difference.

Densitometry was performed on Western Blots and the fold change of cNICD or mNICD in the + inhibitor treated sample relative to the corresponding DMSO control was adjusted to the relative change in the tubulin loading control. The given statistical test was used to compare the average value for each assay to a fixed fold-change value = 1 (i.e. no change) and a p-value obtained.